4-methyl-3-[N-methyl-N-(tetrazol-5-yl)amino]aniline | 152813-70-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-methyl-3-[N-methyl-N-(tetrazol-5-yl)amino]aniline
• 英文别名: 3-N,4-dimethyl-3-N-(2H-tetrazol-5-yl)benzene-1,3-diamine
• CAS: 152813-70-2
• 化学式: C₉H₁₂N₆
• 分子量: 204.234
• InChiKey: SFRGIFVBBIZRSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  三光气 、 (3R)-3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 、 4-methyl-3-[N-methyl-N-(tetrazol-5-yl)amino]aniline 在 三乙胺 作用下， 生成 (+)-N-[3(R)-2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-[4-methyl-3-{N-methyl-N-(tetrazol-5-yl)amino}phenyl]urea
  参考文献：
  名称：

  Controlled Modification of Acidity in Cholecystokinin B Receptor Antagonists:  N-(1,4-Benzodiazepin-3-yl)-N ‘-[3-(tetrazol-5-ylamino)phenyl]ureas

  摘要：

  The design, synthesis, and biological activity of a novel series of CCK-B receptor antagonists (1) which incorporate a tetrazol-5-ylamino functionality attached to the phenyl ring of the arylurea moiety of L-365,260 are described. In these compounds, the acidity of the tetrazole was gradually modified by utilization of simple conformational constraints, and X-ray crystallographic data were obtained to support the conformational dependence of the pK(a) of the aminotetrazoles. Compounds to emerge from the present work such as 1f and 2c,d are among the highest affinity and, in the case of 1f, most selective (CCK-A/CCK-B, 37 000) antagonists so far reported for this receptor. The C-5-cyclohexyl compound 2c (L-736,380) dose-dependently inhibited gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and er vivo binding of [I-125]CCK-8S in BKTO mice brain membranes (ED(50), 1.7 mg/kg) and is one of the most potent acidic CCK-B receptor antagonists yet described.

  DOI：

  10.1021/jm9506736
• 作为产物：
  描述：

  2-氨基-4-硝基甲苯 在 10% palladium on active carbon sodium hydroxide 、 sodium azide 、 sodium hydride 、 氯化铵 作用下， 以 四氢呋喃 、 甲醇 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.82h， 生成 4-methyl-3-[N-methyl-N-(tetrazol-5-yl)amino]aniline
  参考文献：
  名称：

  Controlled Modification of Acidity in Cholecystokinin B Receptor Antagonists:  N-(1,4-Benzodiazepin-3-yl)-N ‘-[3-(tetrazol-5-ylamino)phenyl]ureas

  摘要：

  The design, synthesis, and biological activity of a novel series of CCK-B receptor antagonists (1) which incorporate a tetrazol-5-ylamino functionality attached to the phenyl ring of the arylurea moiety of L-365,260 are described. In these compounds, the acidity of the tetrazole was gradually modified by utilization of simple conformational constraints, and X-ray crystallographic data were obtained to support the conformational dependence of the pK(a) of the aminotetrazoles. Compounds to emerge from the present work such as 1f and 2c,d are among the highest affinity and, in the case of 1f, most selective (CCK-A/CCK-B, 37 000) antagonists so far reported for this receptor. The C-5-cyclohexyl compound 2c (L-736,380) dose-dependently inhibited gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and er vivo binding of [I-125]CCK-8S in BKTO mice brain membranes (ED(50), 1.7 mg/kg) and is one of the most potent acidic CCK-B receptor antagonists yet described.

  DOI：

  10.1021/jm9506736

文献信息

• Benzodiazepine derivatives
  申请人：Merck, Sharp & Dohme Ltd.

  公开号：US05681833A1

  公开（公告）日：1997-10-28

  Compounds of Formula (I), and salts and prodrugs thereof, wherein said formula, R.sup.1 represents certain optionally substituted alkyl or C.sub.3-7 cycloalkyl; R.sup.2 represents (II) or (III), where m is 0, 1, 2 or 3; R.sup.9 is H or C.sub.1-6 alkyl; R.sup.10 is imidazolyl, triazolyl or tetrazolyl, and R.sup.11 is H, C.sub.1-6 alkyl or halo; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.1-7 alkyl, C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkylC.sub.1-4 alkyl, C.sub.6-10 bicycloalkyl, optionally substituted aryl, or NR.sub.12 R.sub.13 ; R.sup.5 is H or C.sub.1-4 alkyl; n is 0, 1, 2 or 3; which are CCK and/or gastrin antagonists useful in therapy.

  公式(I)的化合物，以及它们的盐和前药，其中所述公式中，R.sup.1代表某些可选地取代的烷基或C.sub.3-7环烷基；R.sup.2代表(II)或(III)，其中m为0、1、2或3；R.sup.9为H或C.sub.1-6烷基；R.sup.10为咪唑基、三唑基或四唑基，且R.sup.11为H、C.sub.1-6烷基或卤素；R.sup.3为C.sub.1-6烷基、卤素或NR.sup.6 R.sup.7；R.sup.4为C.sub.1-7烷基、C.sub.3-10环烷基、C.sub.3-10环烷基C.sub.1-4烷基、C.sub.6-10双环烷基、可选地取代的芳基，或NR.sub.12 R.sub.13；R.sup.5为H或C.sub.1-4烷基；n为0、1、2或3；它们是有用的治疗药物，用作CCK和/或胃泌素拮抗剂。
• 3-UREIDO SUBSTITUTED BENZODIAZEPIN-2-ONES HAVING CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTIC ACTIVITY AND THEIR USE IN THERAPY
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0636123A1

  公开（公告）日：1995-02-01
• [EN] 3-UREIDO SUBSTITUTED BENZODIAZEPIN-2-ONES HAVING CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTIC ACTIVITY AND THEIR USE IN THERAPY
  申请人：MERCK SHARP & DOHME LIMITED

  公开号：WO1993019052A1

  公开（公告）日：1993-09-30

  (EN) Compounds of formula (I), and salts and prodrugs thereof. In that said formula, R1 represents certain optionally substitued alkyl or C3-7cycloalkyl; R2 represents (II) or (III), where m is 0, 1, 2 or 3, R9 is H or C1-6alkyl, R10 is imidazolyl, triazolyl or tetrazolyl, and R11 is H, C1-6alkyl or halo; R3 is C1-6alkyl, halo or NR6R7; R4 is C1-7alkyl, C3-10cycloalkyl, C3-10cycloalkylC1-4alkyl, C6-10bicycloalkyl, optionally substituted aryl, or NR12R13; R5 is H or C1-4alkyl; n is 0, 1, 2 or 3; are CCK and/or gastrin antagonists useful in therapy.(FR) Composés de formule (I) et sels et promédicaments relatifs. Dans la formule, R1 représente certains alkyles ou cycloalkyles C3-7 éventuellement substitués; R2 représente (II) ou (III), où m vaut 0, 1, 2 ou 3, R9 représente H ou alkyle C1-6, R10 représente imidazolyle, triazolyle, et R11 représente H, alkyle C1-6 ou halo; R3 représente alkyle C1-6, halo ou NR6R7; R4 représente alkyle C1-7, cycloalkyle C3-10, cycloalkyle C3-10 alkyle C1-4, bicycloalkyle C6-10, aryle éventuellement substitué ou NR12R13; R5 représente H ou alkyle C1-4; n vaut 0, 1, 2 ou 3. Ces composés sont des antagonistes de cholécystokinine et/ou de gastrine utiles en thérapie.
• Controlled Modification of Acidity in Cholecystokinin B Receptor Antagonists:  <i>N</i>-(1,4-Benzodiazepin-3-yl)-<i>N</i> ‘-[3-(tetrazol-5-ylamino)phenyl]ureas
  作者：José L. Castro、Richard G. Ball、Howard B. Broughton、Michael G. N. Russell、Denise Rathbone、Alan P. Watt、Raymond Baker、Kerry L. Chapman、Alan E. Fletcher、Smita Patel、Alison J. Smith、George R. Marshall、Wayne Ryecroft、Victor G. Matassa

  DOI：10.1021/jm9506736

  日期：1996.1.1

  The design, synthesis, and biological activity of a novel series of CCK-B receptor antagonists (1) which incorporate a tetrazol-5-ylamino functionality attached to the phenyl ring of the arylurea moiety of L-365,260 are described. In these compounds, the acidity of the tetrazole was gradually modified by utilization of simple conformational constraints, and X-ray crystallographic data were obtained to support the conformational dependence of the pK(a) of the aminotetrazoles. Compounds to emerge from the present work such as 1f and 2c,d are among the highest affinity and, in the case of 1f, most selective (CCK-A/CCK-B, 37 000) antagonists so far reported for this receptor. The C-5-cyclohexyl compound 2c (L-736,380) dose-dependently inhibited gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and er vivo binding of [I-125]CCK-8S in BKTO mice brain membranes (ED(50), 1.7 mg/kg) and is one of the most potent acidic CCK-B receptor antagonists yet described.